-Even if its clinical presentation varies greatly depending on the patient, spondyloarthritis is a potentially serious and disabling chronic disease that can deteriorate the quality of life and reduce life expectancy.
-It can cause functional restrictions and limitations with a socio-professional impact and an economic repercussion either directly through the cost of the disease or indirectly through the loss of productivity.
|
8,4± 1.4
|
-Spondyloarthritis is a condition that requires a multidisciplinary approach involving medical, paramedical staff and others. -The rheumatologist is the specialist who coordinates the management of spondyloarthritis. -This management must be global, allowing the control of the various dimensions of the disease.
|
9 ± 0
|
-The initial therapeutic objective is to obtain and maintain clinical remission or a low disease activity in order to improve the patient’s quality of life, prevent structural damage and ensure optimal autonomy and social reintegration. -To achieve this goal, a Treat-to-Target (T2T) approach can be implemented and adapted to each patient by including the different clinico-biological parameters of the disease, the extra-articular manifestations and comorbidities as well as the NSAIDs intake.
|
8,7± 0,8
|
-Spondyloarthritis is a heterogeneous chronic inflammatory rheumatic disease characterised by the predominant involvement of the entheses, with axial and/or peripheral rheumatological manifestations as well as extra-articular manifestations associated with a particular genetic background.
-Several phenotypes can be distinguished:
□ Radiographic axial form
□ Non-radiographic axial form
□ Peripheral form (articular and enthesitic)
-The phenotype can be better characterised by adding the possible concomitant extra-rheumatological manifestations.
|
8,9 ± 0.3
|
